Use of Zoledronic Acid in the Treatment of Paget's Disease

View/ Open
Metadata
Show full item recordCitation
Seton, Margaret, and Stephen M. Krane. 2007. Use of zoledronic acid in the treatment of Paget's disease. Therapeutics and Clinical Risk Management 3(5): 913-918.Abstract
This review examines the use of zoledronic acid in the treatment of Paget’s disease of bone. It begins with a brief discussion of the theories of pathogenesis of Paget’s disease, its clinical manifestations, and the history of bisphosphonate treatment in this disorder. Risk of oversuppression of bone by the more potent bisphosphonates and their association with avascular necrosis of the jaw are noted.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376069/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:5310895
Collections
- HMS Scholarly Articles [17767]
Contact administrator regarding this item (to report mistakes or request changes)